Britain hospital death patient Britain

Antibody combo cuts COVID deaths by 20% in very ill seronegative patients

Reading now: 570
www.cidrap.umn.edu

Regeneron's monoclonal antibody treatment lowers the risk of death from COVID-19 by 20% in hospitalized patients with severe illness who haven't produced a natural immune response, according to preliminary results of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) phase 3 trial.

The results were published on the medRxiv preprint server yesterday.Earlier studies had found that Regeneron's combination of casirivimab and imdevimab (REGEN-COV) reduces viral load, leads to a shorter duration of symptoms, and cuts the risk of hospitalization and death in nonhospitalized coronavirus patients, and a small study suggested a clinical benefit in hospitalized COVID-19 patients with no antibody response to infection.

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA